A diversified portfolio of high-value clinical assets

Galenicap operates a diversified portfolio of development programs based on known molecules, each designed to deliver clinically meaningful improvements and clear paths to value creation.

GLCP-004-1

TR Schziphrenia

This program explores an advanced formulation strategy to improve treatment delivery and therapeutic consistency in patients with treatment-resistant schizophrenia. It addresses a population with limited effective options and significant unmet need.

GLCP-048-1

Secondary stroke

This program builds on a strong retrospective clinical signal supported by preclinical evidence, combining dual-mechanism activity with a differentiated sustained-release formulation. It is designed to improve the balance between efficacy and safety, with a clear path toward Phase II validation and potential partnering.

GLCP-092-1

Post Stroke Apathy

This program targets post-stroke apathy and aphasia through the reformulation of a known compound, addressing a significant unmet need in stroke recovery. It is designed to deliver meaningful clinical benefit through a differentiated product strategy.

GLCP-086-1

Neuroprotection (stroke)

This program targets a critical unmet need in patients undergoing thrombectomy following ischemic stroke. By focusing on neuroprotection in a high-acuity setting, it aims to improve clinical outcomes in a patient population where effective adjunctive therapies are currently lacking.

GLCP-046-1

Neuroprotection (stroke)

This program focuses on the repurposing and development of an oral formulation of a known compound for neuroprotection following stroke-induced brain damage. It is designed for rapid administration ("golden hour"), aiming to improve clinical outcomes in the acute phase of stroke.

GLCP-063-1

CIPN

This program focuses on preventing chemotherapy-induced peripheral neuropathy (CIPN), a major complication of cancer treatment. By improving tolerability and patient quality of life, it targets a well-recognized gap in oncology supportive care.

GLCP-008-1

R/R AML

This program focuses on improving tolerability and therapeutic performance in replapsed/refractory AML. It is designed to address the limitations of existing treatments in a patient population with significant unmet need.

GLCP-079-1

Respiratory infections

This program is designed to enhance therapeutic effectiveness in severe respiratory infections through a targeted reformulation approach, addressing increasing clinical complexity and resistance challenges.

GLCP-003-1

Ventricular arrythmias

This program focuses on the reformulation of a known compound into an oral extended-release formulation for the treatment of ventricular arrhythmias, including VT/VF and LQTS. It is designed to improve therapeutic consistency and clinical management in patients at high risk of cardiac events.

A disciplined and scalable portfolio strategy

The portfolio reflects a disciplined and scalable approach to clinical asset development, balancing risk, timelines, and commercial potential across multiple programs. Each asset is selected and designed based on clear scientific rationale, clinical relevance, and a defined path toward differentiation and value creation.

By advancing multiple programs in parallel, Galenicap creates a diversified set of opportunities with distinct value inflection points, enabling both near-term progress and long-term upside. This portfolio-driven model supports a repeatable process for generating high-quality clinical assets and positioning them for strategic partnerships or exit.

A multi-disciplinary screening process

Before advancing any new program, each opportunity undergoes a structured, multi-disciplinary screening process to identify assets with the highest potential for clinical and commercial success. This evaluation integrates clinical, scientific, technical, regulatory, and commercial perspectives from the outset.

Each candidate is assessed against a defined Target Product Profile, with a focus on unmet medical need, clinical relevance, and potential for differentiation. In parallel, we evaluate feasibility, intellectual property, regulatory pathways, and market access to ensure a clear and executable development strategy.

Supported by external experts and clinical key opinion leaders, this approach enables Galenicap to efficiently select and advance programs, maintain a balanced portfolio, and focus on assets with the greatest potential to improve patient outcomes and create value.